CoChat

The therapeutic potential of targeting tryptophan catabolism in cancer

Open access
Opitz, Christiane A., Somarribas Patterson, Luis F., Mohapatra, Soumya R., Dewi, Dyah L., Sadik, Ahmed, Platten, Michael, Trump, Saskia · 2020 · British Journal of Cancer

The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.

Abstract

Based on its effects on both tumour cell intrinsic malignant properties as well as anti-tumour immune responses, tryptophan catabolism has emerged as an important metabolic regulator of cancer progression. Three enzymes, indoleamine-2,3-dioxygenase 1 and 2 (IDO1/2) and tryptophan-2,3-dioxygenase (TDO2), catalyse the first step of the degradation of the essential amino acid tryptophan (Trp) to kynurenine (Kyn). The notion of inhibiting IDO1 using small-molecule inhibitors elicited high hopes of a positive impact in the field of immuno-oncology, by restoring anti-tumour immune responses and synergising with other immunotherapies such as immune checkpoint inhibition. However, clinical trials with IDO1 inhibitors have yielded disappointing results, hence raising many questions. This review will discuss strategies to target Trp-degrading enzymes and possible down-stream consequences of their inhibition. We aim to provide comprehensive background information on Trp catabolic enzymes as targets in immuno-oncology and their current state of development. Details of the clinical trials with IDO1 inhibitors, including patient stratification, possible effects of the inhibitors themselves, effects of pre-treatments and the therapies the inhibitors were combined with, are discussed and mechanisms proposed that might have compensated for IDO1 inhibition. Finally, alternative approaches are suggested to circumvent these problems.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-019-0664-6

Cites

219 of 219 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mode of action and effects of Trp catabolism on cells in the tumour microenvironment. Effects of Trp depletion and Trp metabolites on CD8+ T cells, CD4+ T cells, myeloid cells and tumour cells are shown.
Fig. 1 Mode of action and effects of Trp catabolism on cells in the tumour microenvironment. Effects of Trp depletion and Trp metabolites on CD8+ T cells, CD4+ T cells, myeloid cells and tumour cells are shown.CC BY · PubMed Central
Fig. 2 Analysing IDO1 inhibitors clinical trial results. a Intra-tumoural penetrance of IDO1 inhibitors (IDO1i) could be hindered due to diminished blood supply to tumours or elevated oncotic pressure in solid tumours (left). Even if IDO1i are able to access tumours, ABC transporters can interfere with their intracellular penetrance (middle). Cellular uptake of IDO1i can lead to AHR activation in various cell types and therefore contribute to cancer progression (right). b Combination of IDOi with other types of therapies can lead to the upregulation of IDO1 expression through various mechanisms (see text). In addition, clinical trials have included patients pre-treated with BRAF inhibitors (BRAFi), which were shown to promote an enrichment of a population of cells with constitutive AHR activity. This might further lead to the induction of IDO1 expression and contribute to cancer progression. c Even if IDO1 inhibition is effectively achieved, IDO2 and TDO2 might compensate for IDO1 blockade. BRAFi and IDO1i can promote AHR activation in various cells present in the tumour microenvironment, which unleashes the intrinsic cancer promoting effects driven by the AHR. Moreover, AHR activation leads to the upregulation of IDO2 and TDO2, which can further activate the AHR and deplete Trp. IDO1i and immune check point blockade (ICB) lead to an increase in cytotoxic TILs, which in turn secrete pro-inflammatory molecules, such as IFN-γ, which also induces IDO2. In addition, the pro-inflammatory microenvironment driven by IDO1i and ICB therapy can also lead to the upregulation of TDO2, via the COX2–PGE2–EP4 pathway. d In order to obtain a more robust view of the effects of IDO1 inhibition and improve the outcome of its use in clinical trials, we suggest stratifying patients based on the concentration of Trp, Kyn and Kyn-derived metabolites in plasma and tumours, as well as on the expression of the TCE and AHR activity present in tumours. Once stratified, patients can be treated more accurately with one or more therapies targeting Trp catabolism.
Fig. 2 Analysing IDO1 inhibitors clinical trial results. a Intra-tumoural penetrance of IDO1 inhibitors (IDO1i) could be hindered due to diminished blood supply to tumours or elevated oncotic pressure in solid tumours (left). Even if IDO1i are able to access tumours, ABC transporters can interfere with their intracellular penetrance (middle). Cellular uptake of IDO1i can lead to AHR activation in various cell types and therefore contribute to cancer progression (right). b Combination of IDOi with other types of therapies can lead to the upregulation of IDO1 expression through various mechanisms (see text). In addition, clinical trials have included patients pre-treated with BRAF inhibitors (BRAFi), which were shown to promote an enrichment of a population of cells with constitutive AHR activity. This might further lead to the induction of IDO1 expression and contribute to cancer progression. c Even if IDO1 inhibition is effectively achieved, IDO2 and TDO2 might compensate for IDO1 blockade. BRAFi and IDO1i can promote AHR activation in various cells present in the tumour microenvironment, which unleashes the intrinsic cancer promoting effects driven by the AHR. Moreover, AHR activation leads to the upregulation of IDO2 and TDO2, which can further activate the AHR and deplete Trp. IDO1i and immune check point blockade (ICB) lead to an increase in cytotoxic TILs, which in turn secrete pro-inflammatory molecules, such as IFN-γ, which also induces IDO2. In addition, the pro-inflammatory microenvironment driven by IDO1i and ICB therapy can also lead to the upregulation of TDO2, via the COX2–PGE2–EP4 pathway. d In order to obtain a more robust view of the effects of IDO1 inhibition and improve the outcome of its use in clinical trials, we suggest stratifying patients based on the concentration of Trp, Kyn and Kyn-derived metabolites in plasma and tumours, as well as on the expression of the TCE and AHR activity present in tumours. Once stratified, patients can be treated more accurately with one or more therapies targeting Trp catabolism.CC BY · PubMed Central
Fig. 3 Analytical approaches for quantification expression and activity of tryptophan catabolising enzymes (TCEs) in cancer therapies. The levels of Trp and its metabolites can be measured by chromatographic methods, including high-performance liquid chromatography (HPLC), gas chromatography–mass spectrometry (GC-MS) or liquid chromatography–mass spectrometry (LC-MS).208 Antibodies detecting Trp, as well as specific metabolites of the Trp degradation pathway, enable enzyme-linked immunosorbent assay (ELISA) measurements.163,209–211 Furthermore, matrix-assisted laser desorption/ionisation (MALDI) mass spectrometry (MS) imaging allows visualisation of Trp and Kyn in tissue,90,212 while position-emission tomography (PET) imaging with Trp-derived tracers enables visualisation of Trp uptake in vivo.213–218 In addition, TCE expression can be detected on mRNA and protein levels, however care must be taken when selecting anti-IDO1 antibodies, as many lack selectivity, particularly for immunohistochemistry.27 The blue area of the circle illustrates methods used for measuring Trp and its metabolites; the yellow area illustrates methods used for detcting the expression of TCE and AHR activity. IF: immunofluorescence; WB: Western blot. PET-imaging example was reproduced under a Creative Commons CC-BY license from.219 RNA-seq example was reproduced under a Creative Commons CC-BY license from.220 Western Blot example was provided by the authors.
Fig. 3 Analytical approaches for quantification expression and activity of tryptophan catabolising enzymes (TCEs) in cancer therapies. The levels of Trp and its metabolites can be measured by chromatographic methods, including high-performance liquid chromatography (HPLC), gas chromatography–mass spectrometry (GC-MS) or liquid chromatography–mass spectrometry (LC-MS).208 Antibodies detecting Trp, as well as specific metabolites of the Trp degradation pathway, enable enzyme-linked immunosorbent assay (ELISA) measurements.163,209–211 Furthermore, matrix-assisted laser desorption/ionisation (MALDI) mass spectrometry (MS) imaging allows visualisation of Trp and Kyn in tissue,90,212 while position-emission tomography (PET) imaging with Trp-derived tracers enables visualisation of Trp uptake in vivo.213–218 In addition, TCE expression can be detected on mRNA and protein levels, however care must be taken when selecting anti-IDO1 antibodies, as many lack selectivity, particularly for immunohistochemistry.27 The blue area of the circle illustrates methods used for measuring Trp and its metabolites; the yellow area illustrates methods used for detcting the expression of TCE and AHR activity. IF: immunofluorescence; WB: Western blot. PET-imaging example was reproduced under a Creative Commons CC-BY license from.219 RNA-seq example was reproduced under a Creative Commons CC-BY license from.220 Western Blot example was provided by the authors.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 219 references

Research works printed but not linked: 4

  1. Hennequart Marc Pilotte Luc Cane Stefania Hoffmann Delia Stroobant Vincent Plaen Etienne De Eynde Benoît J. Van den Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance Cancer Immunology Research 2017 5 8 695 709 28765120 · DOI · Paper page
  2. Gibney, G. T., Hamid, O., Lutzky, J., Olszanski, A. J., Mitchell, T. C., Gajewski, T. F. et. al. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J. Immunother. Cancer7, 80 (2019). PMC6425606 30894212 · DOI · Paper page
  3. Spranger S Koblish HK Horton B Scherle PA Newton R Gajewski TF Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+T cells directly within the tumor microenvironment J. ImmunoTher. Cancer 2014 2 1 14 24829760 PMC4019906 · DOI · Paper page
  4. Ochs K Ott M Rauschenbach KJ Deumelandt K Sahm F Opitz CA Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4 J. Neurochem. 2015 136 1142 1154 26708701 · DOI · Paper page

Cited by

See all 303

Metadata

Authors
Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S.
Affiliations
  • German Cancer Research Center (DE)
  • Universitas Gadjah Mada (ID)
  • Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
Corresponding author
Opitz, Christiane A.
Venue
British Journal of Cancer
Published
2019-12-10
Volume
122
Issue
1
Pages
30-44
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2993480792
Cited by
300
References
219
Citations by year
2026: 43 · 2025: 46 · 2024: 48 · 2023: 47 · 2022: 49 · 2021: 51 · 2020: 12 · 2019: 3
FWCI
2.76
Type
journal article
Language
en
Open access
Licence
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • EC | Horizon 2020 Framework Programme (No 754688, No 643638)
  • Bundesministerium für Bildung und Forschung (01ZX1402)
  • University of Costa Rica | Vicerrectoría de Investigación, Universidad de Costa Rica
  • Costa Rica’s Ministry of Science, Technology and Telecommunications
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
tryptophan catabolism, kynurenine pathway, IDO1, IDO2, tryptophan 2,3-dioxygenase, IDO1 inhibitors, cancer immunotherapy, antitumor immunity, immune checkpoint inhibitors, cancer metabolism, clinical trials, patient stratification
MeSH terms
Animals, Enzyme Inhibitors, Humans, Immunotherapy, Kynurenine, Neoplasms, Tryptophan, Tryptophan Oxygenase, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The therapeutic potential of targeting tryptophan catabolism in cancer. https://app.cochat.ai/papers/10.1038/s41416-019-0664-6
The paper
Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020). The therapeutic potential of targeting tryptophan catabolism in cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-019-0664-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.